Industry Wary Of OTC Monograph User-Fees Concept
This article was originally published in The Rose Sheet
Executive Summary
Executives from OTC drug manufacturers expressed doubts at a June 10 public meeting about the equity and utility of a program FDA is considering that would impose user fees on firms that make or market monograph drugs, the vast majority of nonprescription pharmaceutical products.